Intelligent Bio Solutions announced the completion of a usability study for its fingerprinting drug screening system, a key step for its FDA 510(k) submission to detect codeine. This development is a positive incremental step towards potential U.S. market clearance, which could expand the company's market reach.
Intelligent Bio Solutions (INBS) has completed a usability study for its Intelligent Fingerprinting Drug Screening System, specifically for the detection of opiate codeine. This is a crucial step in their FDA 510(k) submission process, which is required for U.S. market clearance. The completion of this study indicates progress towards regulatory approval, which, if granted, would allow INBS to commercialize this product in the United States, significantly expanding its potential market. For traders, this represents a positive incremental development, de-risking the regulatory pathway somewhat. While not a definitive approval, it's a necessary milestone that could lead to long-term revenue growth for INBS, making it an opportunity for those bullish on the company's regulatory success.